Type 2 Diabetes Mellitus
Conditions
Keywords
Type 2 diabetes, Uncontrolled blood glucose, insulin, glargine, NPH
Brief summary
The goal of the current study is to determine difference in glycemic control between traditional split mix regimen with Neutral Protamine Hagedorn (NPH) and regular insulin vs basal bolus regimen with glargine and humalog in a population of type 2 diabetes commonly encountered in the investigators county hospital setting which include newly diagnosed type 2 patients and patients on relatively high dose of insulin (dose \>0.4 units/kg body weight. Primary outcome of the study is to determine differences in glycemic control between treatment group as measured by the mean daily blood glucose. Secondary outcome is to measure number of hypoglycemic events, number of severe hypoglycemia and length of hospital stay.
Detailed description
The effect of insulin depends not only on the pharmacokinetics and pharmacodynamics of a particular preparation, but also on patient specific factors which includes state of inflammation, obesity etc. Although effect on glucose disposal is the central to insulin action, there could be differences of insulin action on other metabolic parameters. It is not known if there is a difference in suppression of inflammation with improved glycemic control which could vary with analog insulin. It is unknown if natural insulin (NPH, recombinant human insulin with protamine) differs from insulin analogs (glargine and detemir, made by substituting amino acid in the native sequence) in terms of metabolic outcome other than glucose disposal. At this point it is uncertain if there is any clear benefit of use of lantus over NPH in inpatient glycemic management. Currently, both lantus and NPH based regimen is practiced in inpatient hospital setting. Current practice of inpatient insulin regimen is based more on familiarity of physicians with a particular insulin type and personal preference rather than evidenced based knowledge. Lantus is an expensive insulin preparation compared to NPH with uncertain benefit in inpatient setting. Current research proposal will compare this two insulin based regimen in the management of diabetes of hospitalized patients. Information obtained through this research will guide the investigators practice in this institution as well as in other institutions.
Interventions
DRUGNPH and regular insulin
DRUGglargine and humalog
Sponsors
Riverside University Health System Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with type II diabetes regardless of duration of diagnosis with an admission blood glucose level between 140 mg/dL to 400 mg/dL will be included in the study. * Other inclusion criteria are as follows: * age 18-80 years old * treated with diet alone * any combination of oral anti-diabetic agents or insulin treatment with any dosage before admission.
Exclusion criteria
* Hyperglycemia without a known history of diabetes * H/o recent cardiac surgery (within 6 months) * Impaired renal function (glomerular filtration rate less than 45) * History of diabetic ketoacidosis * Diabetes mellitus type 1 * Pregnancy * Patients on steroid treatment * Known hypopituitarism or adrenal insufficiency * Known hypoglycemia of unawareness * Length of stay \<48 h * And severe liver disease and patent admitted in intensive care unit. * Patients already received an insulin dose greater than 0.5 units/kg body weight after admission prior to initiation of study protocol will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| difference in glycemic control between treatment groups as measured by the mean daily blood glucose | Duration of hospital stay, up to 24 weeks | Primary outcome of the study is to determine differences in glycemic control between treatment group as measured by the mean daily blood glucose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| number of hypoglycemic events | duration of hospital stay, up to 24 weeks | number of hypoglycemic events |
Countries
United States
Outcome results
None listed